This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Malcolm C. Pike, PhD; Leslie Bernstein, PhD; Ronald K. Ross, MD; Brian E. Henderson, MD
University of Southern California School of Medicine Los Angeles

JAMA. 1991;265(14):1824.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Colditz et al¹ from the Nurses' Health Study conclude that there is a statistically significant elevation of 36% in breast cancer risk that is limited to current users of estrogen replacement therapy, and that there is no relationship with duration of use. The report, however, does not consider an important risk factor for breast cancer: age at menopause. Although this is most unlikely to alter the conclusion about an elevation in breast cancer risk associated with use of estrogen replacement therapy, it raises serious doubts about the relationship's being restricted to current users and about there being no relationship with duration of use.

It is generally accepted that earlier ages at menopause are associated with lower risks of breast cancer,² and we have found that women with early menopause have greater use of replacement hormones.³ If use of estrogen replacement therapy is associated with . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?